A method for enhancing the stability of alpha-synuclein aggregates
High stability and enhanced neurotoxicity of α-synuclein aggregates in Parkinson's disease plasma were determined by incubating recombinant human α-synuclein in plasma of Parkinson's disease and performing trypsin and protease K digestion experiments. , solved the gap in this problem in existing studies and provided a basis for the study of the pathogenesis of Parkinson's disease.
Patent Information
- Application Number
- CN202111597996.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-12-24
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2041-12-24
AI Technical Summary
In the existing studies, it has not yet been clarified whether the α-synuclein aggregates formed by plasma incubation of Parkinson's disease patients have higher stability and affect their neurotoxicity.
Recombinant human α-synuclein was incubated with plasma of healthy controls and Parkinson's disease patients with plasma, and digestion experiments were performed using trypsin and protease K, and the degradation of aggregates was evaluated in combination with Western blotting method. Statistical method The stability differences between different groups were analyzed.
It is proved that the α-synuclein aggregates formed after Parkinson's plasma incubation have stronger resistance to trypsin and protease K and have higher stability, providing an experimental basis for studying the pathogenesis of Parkinson's disease.
Smart Images

Figure CN114324892B_ABST
Abstract
Description
[Technical field]
[0001] The invention belongs to the technical field of alpha-synuclein aggregates and relates to a method for enhancing the stability of alpha-synuclein aggregates. [Background technology]
[0002] Synucleinopathies are a class of neurodegenerative diseases characterized by abnormal aggregation of α-synuclein (α-Syn), including Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). α-Syn is a soluble protein composed of 140 amino acids, mostly distributed in presynaptic terminals in the form of monomers. Under physiological conditions, α-Syn exists mainly in disordered and α-helical states; under pathological conditions, α-Syn is prone to aggregation, first forming soluble oligomers, and then assembling into ordered, β-fold-rich insoluble amyloid fibrils, which further aggregate to form intracellular inclusions, becoming the hallmark pathological structure of synucleinopathies. The results showed that the stability of the hallmark pathological structures of different synucleinopathies was different. For example, compared with the hallmark pathological structure of PD, the hallmark pathological structure of MSA, glial cytoplasmic inclusions (GCIs), had stronger resistance to proteinase K (PK), and α-Syn derived from GCIs could cause more severe neuropathological changes in mice, suggesting that the α-Syn of the two may have different protein conformations. The conformational state of α-Syn is affected by pH, temperature, ionic strength, and viscosity, and it can self-assemble and aggregate in vivo and in vitro, and the aggregates formed can spread in a prion-like manner in the form of "seeds".
[0003] There have been studies on α-synuclein, such as Chinese patent application No. CN201910419084.5 on the use of Fast Green in the preparation of α-synuclein aggregation inhibitors, and the use of Fast Green in the preparation of drugs, health products or foods for preventing and / or treating diseases characterized by aggregation and precipitation of α-synuclein. The proposed use of Fast Green in inhibiting α-synuclein aggregation can effectively inhibit α-synuclein aggregation, effectively prevent the occurrence of PD and delay the development of PD, and effectively inhibit the toxicity of α-synuclein aggregates to cells, inhibit the aggregation of α-synuclein and its conformational change process, and is an ideal drug for the treatment and prevention of Parkinson's disease.
[0004] Protease resistance test is a common and effective method to evaluate the stability of amyloid protein. Studies have found that both trypsin and PK can lead to the degradation of mature amyloid fibrils, including the degradation of misfolded proteins. Studies have found that changes in the metabolic environment of PD patients' plasma are conducive to the aggregation of α-Syn and produce more obvious neurotoxicity, but it is not clear whether the α-Syn aggregates formed by incubation of PD patient plasma have higher stability. [Summary of the invention]
[0005] In view of the existing research, it is still unclear whether the α-synuclein (abbreviated as α-Syn) aggregates formed by incubation in PD patient plasma have higher stability. The present invention provides a method for enhancing the stability of α-synuclein aggregates, which provides a basis for subsequent research on the different neurotoxic differences of α-synuclein aggregates formed by incubation under different conditions.
[0006] The purpose of the present invention is achieved through the following technical solutions:
[0007] A method for enhancing the stability of alpha-synuclein aggregates comprises the following steps:
[0008] 1) Preparation of α-synuclein aggregates:
[0009] 1 mg of recombinant human α-synuclein was dissolved in 140 μL 0.01 M PBS (phosphate buffer solution, PBS), and 70 μL of PBS, HC plasma (healthy control, HC) or PD plasma was added to obtain PBS group, HC group and PD group, so that the final concentration of α-synuclein was 5 mg / mL. A certain amount of preservative was added to inhibit bacterial growth, and the mixture was incubated at 1000 rpm in a 37°C constant temperature shaking mixer for 7 days; the protein concentration after incubation was determined by BCA method, and the mixture was stored at -80°C after aliquoting for later use;
[0010] 2) Trypsin digestion of α-synuclein aggregates:
[0011] Trypsin was mixed with 10 μg of α-synuclein aggregates from each group of PBS, HC, and PD at a ratio of 1:80, 1:40, and 1:20, respectively, and made up to a final volume of 20 μL with 0.01 M PBS. After digestion at 37°C for 30 min, the samples were denatured, and the degradation of α-synuclein aggregates after trypsin digestion was evaluated by Western blotting (WB);
[0012] 3) Proteinase K digestion of α-synuclein aggregates:
[0013] 1, 1.5, and 2 μg / mL proteinase K were mixed with 10 μg of α-synuclein aggregates in each group of PBS, HC, and PD, respectively, and made up to a final volume of 20 μL with 0.01 M PBS. After incubation at 37°C for 30 min, the degradation of α-synuclein aggregates after proteinase K digestion was evaluated by WB method;
[0014] 4) WB method was used to detect the expression difference of α-synuclein aggregates:
[0015] After separating 800 ng of α-synuclein protein in each of the PBS, HC and PD groups by polyacrylamide gel electrophoresis, the protein was transferred to a PVDF membrane; blocked with 5% skim milk powder at room temperature for 1 h; incubated with anti-α-synuclein monoclonal antibody at room temperature for 2 h; incubated with goat anti-rabbit fluorescent secondary antibody at room temperature for 1 h, the membrane was scanned and imaged using the ODYSSEY two-color infrared fluorescence imaging system.
[0016] 5) Statistical methods:
[0017] Image J software was used for image grayscale analysis, and GraphPad Prism 8.0.2 software was used for data statistics and analysis. The quantitative data were expressed as mean ± standard deviation. The means among the groups were compared using one-way analysis of variance combined with Tukey's multiple comparison test, and P < 0.05 was considered statistically significant.
[0018] In the present invention:
[0019] The preservative added in step 1) is 0.02% (v / v) Proclin 300.
[0020] The anti-α-synuclein monoclonal antibody in step 4) is selected from the ab138501 monoclonal antibody of Abcam, with a dilution ratio of 1:10000.
[0021] The goat anti-rabbit fluorescent secondary antibody in step 4) is selected from LICOR 926-68071 antibody, with a dilution ratio of 1:10000.
[0022] Compared with the prior art, the present invention has the following advantages:
[0023] 1. A method for enhancing the stability of α-synuclein aggregates described in the present invention uses phosphate buffer solution (PBS), healthy control (HC) plasma and PD patient plasma to incubate α-synuclein to obtain different α-synuclein aggregates. The present invention shows that the α-synuclein aggregates formed after incubation with PD plasma are highly stable, indicating that the metabolic environment of PD causes the α-synuclein aggregates to be more stable, thereby increasing their toxicity. This α-synuclein aggregate is conducive to PD modeling and lays the foundation for studying the pathogenesis of PD.
[0024] 2. The method for enhancing the stability of α-synuclein aggregates described in the present invention uses trypsin (Trypsin) and proteinase K (PK) digestion experiments to compare and analyze the differences in the stability of α-synuclein aggregates formed by incubation with PBS, HC and PD patient plasma, and proves that the α-synuclein aggregates formed after incubation with PD plasma are more resistant to Trypsin and PK digestion and have stronger stability.
[0025] 3. The method for enhancing the stability of α-synuclein aggregates described in the present invention provides an experimental basis for exploring the differences in neurotoxicity of α-synuclein aggregates formed by incubation under different conditions.
Brief Description of the Drawings
[0026] Figure 1 It is a diagram of the formation of α-Syn aggregates in PFF, PBS, HC and PD groups detected by WB experiment in the experimental example of the present invention;
[0027] Figure 2 is a graph of a WB experiment evaluating the digestion effect of different concentrations of Trypsin on α-Syn PFF in an experimental example of the present invention;
[0028] Figure 3 is a graph of the WB experiment evaluating the digestion effect of different concentrations of Trypsin on α-Syn in PBS, HC and PD groups in the experimental examples of the present invention;
[0029] Figure 4 is a graph of a WB experiment evaluating the digestion effect of different concentrations of PK on α-Syn PFF in an experimental example of the present invention;
[0030] Figure 5 This is a graph showing the WB experiment in the experimental example of the present invention evaluating the digestion effect of different concentrations of PK on α-Syn in PBS, HC and PD groups. [Specific implementation method]
[0031] The specific implementation modes of the present invention are further described below in conjunction with examples.
[0032] Example:
[0033] A method for enhancing the stability of alpha-synuclein aggregates comprises the following steps:
[0034] 1) Preparation of α-Syn aggregates:
[0035] 1 mg of recombinant human α-Syn was dissolved in 140 μL 0.01 M PBS, and 70 μL of PBS, HC plasma or PD plasma was added to obtain PBS group, HC group and PD group, respectively, so that the final concentration of α-Syn was 5 mg / mL. A certain amount of preservative (0.02% (v / v) Proclin 300) was added to inhibit bacterial growth, and the cells were incubated at 37°C constant temperature shaking mixer at 1000 rpm for 7 days; the protein concentration after incubation was determined by BCA method, and the cells were stored at -80°C after aliquoting for later use;
[0036] 2) Trypsin digestion of α-Syn aggregates:
[0037] Trypsin was mixed with 10 μg of α-Syn aggregates from each group of PBS, HC, and PD at a ratio of 1:80, 1:40, and 1:20, respectively, and made up to a final volume of 20 μL with 0.01 M PBS. After digestion at 37°C for 30 min, the cells were denatured, and the degradation of α-Syn aggregates after trypsin digestion was evaluated by Western blotting (WB);
[0038] 3) PK digestion of α-Syn aggregates:
[0039] 1, 1.5, and 2 μg / mL PK were mixed with 10 μg of α-Syn aggregates in each group of PBS, HC, and PD, respectively, and made up to a final volume of 20 μL with 0.01 M PBS. After incubation at 37°C for 30 min, the degradation of α-Syn aggregates after PK digestion was evaluated by WB method;
[0040] 4) WB method to detect the expression difference of α-Syn aggregates:
[0041] After separating 800 ng of α-Syn protein in each of the PBS, HC and PD groups by polyacrylamide gel electrophoresis, the proteins were transferred to PVDF membranes; blocked with 5% skim milk powder at room temperature for 1 h; incubated with anti-α-Syn monoclonal antibody (dilution ratio 1:10000) at room temperature for 2 h; incubated with goat anti-rabbit fluorescent secondary antibody (dilution ratio 1:10000) at room temperature for 1 h, the membrane was scanned and imaged using the ODYSSEY two-color infrared fluorescence imaging system.
[0042] 5) Statistical methods:
[0043] Image J software was used for image grayscale analysis, and GraphPad Prism 8.0.2 software was used for data statistics and analysis. The quantitative data were expressed as mean ± standard deviation. The means among the groups were compared using one-way analysis of variance combined with Tukey's multiple comparison test, and P < 0.05 was considered statistically significant.
[0044] Experimental example:
[0045] 1. Experimental Materials
[0046] 1. Peripheral blood samples were collected from 10 patients with PD diagnosed in the Department of Neurology, Affiliated Hospital of Guilin Medical College from June 2020 to December 2020, including 5 males and 5 females. Inclusion criteria for PD patients: history of progressive disease, obvious typical symptoms of PD—resting tremor, bradykinesia, rigidity, and postural instability, with at least one of the two symptoms of resting tremor or muscle rigidity, and age between 50 and 80 years old.
[0047] Exclusion criteria: (1) Parkinson's disease patients also have other cerebrovascular diseases, neurological diseases or genetic metabolic diseases; (2) patients who have recently undergone other major surgeries or other organic diseases that may affect the blood; (3) patients with recent anemia or receiving drug treatment for anemia; (4) patients with drug abuse or alcoholism. Blood samples from healthy controls were obtained from 10 healthy people with matched age and gender who had no diabetes, hypertension or neurological diseases. All selected participants signed informed consent. This application was approved by the Ethics Committee of the Affiliated Hospital of Guilin Medical College (JYSLL202137). Peripheral venous blood from PD patients and healthy controls was collected using lithium heparin anticoagulant tubes, and plasma and blood cells were separated by centrifugation at room temperature at 3000 rpm for 15 minutes. Plasma and blood cells were respectively divided into 1.5 mL centrifuge tubes and frozen at -80°C for later use.
[0048] 2. Main reagents: Recombinant human α-Syn protein was donated by Professor Yu Shun of Xuanwu Hospital, Capital Medical University; rabbit anti-α-Syn monoclonal antibody was purchased from Abcam; goat anti-rabbit fluorescent secondary antibody was purchased from LI-COR, USA; recombinant human α-Syn preformed fibrils (PFFs) were purchased from StressMarq, Canada; Trypsin was purchased from Sigma-Aldrich, USA; PK was purchased from Sigma-Aldrich, USA; 5 SDS-PAGE protein loading buffer was purchased from Beijing Solebow Technology Co., Ltd., China; BCA protein quantification kit was purchased from Thermo Scientific, USA; polyvinylidene fluoride (PVDF) membrane was purchased from Millipore, USA.
[0049] 3. Main instruments: Constant temperature oscillating mixer was purchased from Thermo Scientific, USA; electric constant temperature incubator was purchased from Beijing Zhongke Environmental Testing Instrument Co., Ltd., China; electrophoresis apparatus and electrotransfer apparatus were purchased from Bio-Rad, USA; ODYSSEY two-color infrared fluorescence imaging system was purchased from LI-COR, USA.
[0050] 2. Experimental Methods
[0051] 1. Preparation of α-Syn aggregates:
[0052] 1 mg of recombinant human α-Syn was dissolved in 140 μL 0.01 M PBS, and 70 μL of PBS, HC plasma or PD plasma (PBS group, HC group, PD group) was added to make the final concentration of α-Syn 5 mg / mL. A certain amount of preservative was added to inhibit bacterial growth; the mixture was incubated at 1000 rpm in a 37°C constant temperature oscillating mixer for 7 days; the protein concentration after incubation was determined by the BCA method, and the mixture was stored at -80°C for later use after aliquoting;
[0053] 2. Trypsin digestion of α-Syn aggregates:
[0054] Trypsin was mixed with 10 μg of α-Syn aggregates from each group of PBS, HC, and PD at a ratio of 1:80, 1:40, and 1:20, respectively, and made up to a final volume of 20 μL with 0.01 M PBS. After digestion at 37°C for 30 min, the cells were denatured, and the degradation of α-Syn aggregates after trypsin digestion was evaluated by Western blotting (WB);
[0055] 3. PK digestion of α-Syn aggregates:
[0056] 1, 1.5, and 2 μg / mL PK were mixed with 10 μg of α-Syn aggregates in each group of PBS, HC, and PD, respectively, and made up to a final volume of 20 μL with 0.01 M PBS. After incubation at 37°C for 30 min, the degradation of α-Syn aggregates after PK digestion was evaluated by WB method;
[0057] 4. WB method to detect the expression difference of α-Syn aggregates:
[0058] After separating 800 ng of α-Syn protein in each group of PBS, HC and PD by polyacrylamide gel electrophoresis, the protein was transferred to PVDF membrane; blocked with 5% skim milk powder at room temperature for 1 h; incubated with anti-α-Syn monoclonal antibody (dilution ratio 1:10000) at room temperature for 2 h; incubated with goat anti-rabbit fluorescent secondary antibody (dilution ratio 1:10000) at room temperature for 1 h, and then scanned and imaged using ODYSSEY dual-color infrared fluorescence imaging system;
[0059] 3. Statistical methods:
[0060] Image J software was used for image grayscale analysis, and GraphPad Prism 8.0.2 software was used for data statistics and analysis. The quantitative data were expressed as mean ± standard deviation. The means among the groups were compared using one-way analysis of variance combined with Tukey's multiple comparison test, and P < 0.05 was considered statistically significant.
[0061] result
[0062] 1. Basic characteristics of the subjects
[0063] There was no significant difference in age and gender between the HC and PD groups (P>0.05). See Table 1 for details.
[0064] Table 1 Comparison of basic characteristics of subjects in the HC and PD groups
[0065] Tab.1Characteristic comparison of subjects between HC and PD groups(Mean±SD)
[0066] Group Gender (male / female) Age (years) Disease duration (years) HC group 5 / 5 64.1±6.12 - PD group 5 / 5 61.1±5.84 6.25±5.32 F-number 0.000 1.13 - P-value - 0.30 -
[0067] HC group: healthy control group; PD group: Parkinson's disease group
[0068] 2. Differences in the formation of α-Syn aggregates after incubation with PBS, HC, and PD plasma
[0069] WB results showed that after incubation with PBS, HC and PD plasma, the relative molecular weight of α-Syn protein monomers in each group was about 18kDa, and the level and size of aggregates were significantly different. Among them, the α-Syn aggregates in the α-Syn PFF group and the PBS group were mainly concentrated at a relative molecular weight of about 36kDa (dimer) and 72kDa (tetramer); higher molecular weight aggregates were formed in the HC and PD groups. In addition to a small amount of dimers and tetramers, the α-Syn aggregates were mainly concentrated at a relative molecular weight of about 90kDa (pentamer) and 108kDa (hexamer); compared with the HC group, the PD group had more α-Syn aggregates, and the difference was statistically significant (P<0.05). For details, see Figure 1 .
[0070] A: WB electrophoresis bands; B: relative quantitative comparison of α-Syn dimer protein in each group; C: relative quantitative comparison of aggregated proteins above α-Syn dimer in each group;
[0071] PFF: recombinant human α-Syn pre-formed fibrils; PBS: phosphate buffered saline; HC: healthy control plasma; PD: Parkinson's disease plasma; compared with the PFF group, a P<0.05; compared with PBS group, b P<0.05; compared with HC group, c P<0.05
[0072] Figure 1 :WB experiment detected the formation of α-Syn aggregates in PFF, PBS, HC and PD groups (Fig.1WB analysis ofα-Syn aggregates in PFF,PBS,HC and PD groups).
[0073] 3. Differences in α-Syn aggregates in Trypsin-digested PFF, PBS, HC, and PD groups
[0074] As the concentration of Trypsin increased, PFF gradually decreased. When the ratio of Trypsin to α-Syn PFF protein concentration was increased to 1:20, α-Syn aggregates with a molecular weight greater than 35 kDa were basically completely digested, and the difference was statistically significant (P<0.05). Figure 2 .
[0075] Figure 2:WB experiment evaluates the digestion of α-Syn PFF with different concentrations of Trypsin (Fig.2Evaluation of the digestion of α-Syn PFF with different concentrations of Trypsin by WB), where:
[0076] A: WB electrophoresis bands; BD: Relative quantitative comparison of monomers (B), dimers (C) and aggregates larger than dimers (D) after digestion of α-Syn PFF with different concentrations of Trypsin.
[0077] Trypsin: α-Syn: Trypsin and α-Syn PFF concentration ratio (μg / μL:μg / μL); compared with group 0, a P<0.05; compared with the 1:80 group, b P<0.05; compared with the 1:40 group, c P<0.05
[0078] After trypsin digestion of PBS, HC and PD histones, α-Syn showed different degrees of degradation. At <25kDa, with the increase of trypsin concentration, α-Syn in PBS, HC and PD groups decreased to a certain extent. Compared with HC and PD groups, the decrease in PBS group was more significant, and the difference was statistically significant (P<0.05). At 25-40kDa, with the increase of trypsin concentration, α-Syn in PBS, HC and PD groups decreased significantly, among which the decrease in PBS group was significantly higher than that in HC and PD groups, and the decrease in HC group was higher than that in PD group. The degree of digestion in PBS group>HC group>PD group, and the difference was statistically significant (P<0.05). At >40kDa, when the ratio of Trypsin to protein concentration was 1:80, only the PBS group showed a significant decrease in α-Syn; when the concentration increased to 1:40, the HC group showed a significant decrease in α-Syn; when the concentration increased to 1:20, the PD group showed a significant decrease in α-Syn. The degree of digestion was PBS group>HC group>PD group, and the difference was statistically significant (P<0.05). Figure 3 .
[0079] A: WB electrophoresis bands; BD: Comparison of the relative quantitative ratios of α-Syn monomers (B), dimers (C) and aggregates above dimers (D) in the PBS, HC and PD groups after digestion with different concentrations of Trypsin and before digestion (group 0);
[0080] Trypsin: α-Syn: Concentration ratio of Trypsin to α-Syn (μg / μL:μg / μL); at the same concentration, compared with the PBS group, a P<0.05; compared with HC group, b P<0.05
[0081] Figure 3 :WB experiment evaluates the digestion of α-Syn in PBS, HC and PD groups with different concentrations of Trypsin by WB
[0082] 4. Differences in the expression of α-Syn aggregates in PK-digested PFF, PBS, HC and PD groups
[0083] As the PK concentration increased, α-Syn PFF gradually decreased. When the PK concentration was 1 μg / mL, the protein at >25 kDa was completely digested, and the α-Syn monomer at <25 kDa was significantly reduced and small molecular fragments appeared. The higher the PK concentration, the higher the degree of monomer digestion, and the difference was statistically significant (P<0.05). For details, see Figure 4 :
[0084] A: WB electrophoresis bands; BD: Relative quantitative comparison of monomers (B), dimers (C) and aggregates above dimers (D) after digestion of α-Syn PFF with different concentrations of PK, compared with the group with PK concentration of 0 μg / mL. a P<0.05
[0085] Figure 4 :WB experiment evaluated the digestion of α-Syn PFF with different concentrations of PK by WB (Fig.4Evaluation of the digestion of α-Syn PFF with different concentrations of PK by WB).
[0086] PK showed different degrees of degradation ability on α-Syn protein in PBS, HC and PD groups. At <25kDa, α-Syn monomers in PBS group were digested into smaller fragments, and the ratio of protein content of sheared fragments to undigested protein content after digestion increased with the increase of PK concentration, while no obvious digestion was observed in α-Syn monomers in HC and PD groups, and the difference was statistically significant (P<0.05). At 25-40kDa, as the PK concentration increased, the α-Syn dimer in PBS group decreased significantly, and the degree of digestion increased significantly; the α-Syn dimer in HC group increased with the increase of PK concentration; while the amount of α-Syn dimer in PD group did not change significantly with the increase of PK concentration. At >40kDa, as the PK concentration increased, α-Syn in PBS, HC and PD groups decreased to a certain extent. Compared with HC and PD groups, the decrease of α-Syn in PBS group was more significant, and the degree of digestion was PBS group>HC group>PD group, and the difference was statistically significant (P<0.05). For details, see Figure 5 :
[0087] A: WB electrophoresis bands; B: Comparison of the relative quantitative ratios of the sheared band and the unsheared band of α-Syn monomer in each group of PBS, HC, and PD after digestion with different concentrations of PK; C, D: Comparison of the relative quantitative ratios of α-Syn dimers (C) and aggregates above dimers (D) in each group of PBS, HC, and PD after digestion with different concentrations of PK and before digestion (0μg / mL group);
[0088] Sheared band: band below 18kDa; Unsheared band: band at 18kDa; at the same concentration, compared with the PBS group, a P<0.05; compared with HC group, b P < 0.05;
[0089] Figure 5 :WB experiment evaluated the digestion of α-Syn in PBS, HC and PD groups with different concentrations of PK by WB (Fig.5Evaluation of the digestion of α-Syn in PBS, HC and PD groups with different concentrations of PK by WB).
[0090] The above description is a detailed description of the preferred feasible embodiments of the present invention, but the embodiments are not intended to limit the scope of the patent application of the present invention. All equivalent changes or modified changes completed under the technical spirit suggested by the present invention should fall within the patent scope covered by the present invention.
Claims
1. A method for enhancing the stability of α-synuclein aggregates, characterized in that: The steps include: 1) Preparation of α-synuclein aggregates: 1 mg of recombinant human α-synuclein was dissolved in 140 μL 0.01 M PBS, and 70 μL PD plasma was added to obtain a PD group, so that the final concentration of α-synuclein was 5 mg / mL. A preservative was added to inhibit bacterial growth, and the mixture was incubated at 37°C in a constant temperature shaking mixer at 1000 rpm for 7 days. The protein concentration after incubation was determined by the BCA method, and the mixture was stored at -80°C for later use after aliquoting. 2) Trypsin digestion of α-synuclein aggregates: Trypsin was mixed with 10 μg of α-synuclein aggregates from the PD group at a ratio of 1:80, 1:40, and 1:20, respectively, and made up to a final volume of 20 μL with 0.01 M PBS. After digestion at 37°C for 30 min, the cells were denatured, and the degradation of α-synuclein aggregates after trypsin digestion was evaluated by Western blotting; 3) Proteinase K digestion of α-synuclein aggregates: 1, 1.5, and 2 μg / mL proteinase K were mixed with 10 μg of α-synuclein aggregates from the PD group, respectively, and made up to a final volume of 20 μL with 0.01 M PBS. After incubation at 37°C for 30 min, the cells were denatured, and the degradation of α-synuclein aggregates after proteinase K digestion was evaluated by WB method; 4) WB method was used to detect the expression difference of α-synuclein aggregates: After separating 800 ng of α-synuclein from the PD group by polyacrylamide gel electrophoresis, the protein was transferred to a PVDF membrane; the membrane was blocked with 5% skim milk powder at room temperature for 1 h; the anti-α-synuclein monoclonal antibody was incubated at room temperature for 2 h; the membrane was scanned and imaged using the ODYSSEY dual-color infrared fluorescence imaging system after incubating with goat anti-rabbit fluorescent secondary antibody at room temperature for 1 h; 5) Statistical methods: Image J software was used for image grayscale analysis, GraphPad Prism 8.0.2 software was used for data statistics and analysis, and the quantitative data were expressed as mean ± standard deviation. The means among the groups were compared using one-way analysis of variance combined with Tukey's multiple comparison test, and P < 0.05 was considered statistically significant.
2. A method for enhancing the stability of α-synuclein aggregates according to claim 1, characterized in that: The preservative added in step 1) is 0.02% v / v Proclin 300.
3. A method for enhancing the stability of α-synuclein aggregates according to claim 1, characterized in that: The anti-α-synuclein monoclonal antibody in step 4) is selected from the ab138501 monoclonal antibody of Abcam, with a dilution ratio of 1:10000.
4. A method for enhancing the stability of α-synuclein aggregates according to claim 1, characterized in that: The goat anti-rabbit fluorescent secondary antibody in step 4) is selected from LICOR 926-68071 antibody, with a dilution ratio of 1:10000.
Citation Information
Patent Citations
Application of fast green in preparation of alpha-synuclein aggregation inhibitor
CN110179778A
Method for detecting subject humoral disease related protein polymerizing power
CN101308144A
Method for detecting capability of subject body fluid for promoting phosphorylation modification of disease related protein in vitro
CN103954763A
Method for detecting hemoglobin-combined phosphorylated alpha-synuclein
CN104215777A
Method for producing a standard for detecting protein aggregates of a protein misfolding disease, as well as a standard and the use thereof
CN107430122A
